Table 2 AKR1C3 expression and clinicopathological features in PCa and BPH samples
From: AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression
Variables | Cases of PCa | BPH | ||||
|---|---|---|---|---|---|---|
GS = 6 | GS = 7 | GS = 8 | GS = 9 | |||
Age (years) | <60 | 2 | 2 | 0 | 3 | 3 |
61-75 | 6 | 4 | 6 | 4 | 5 | |
>75 | 2 | 4 | 4 | 4 | 3 | |
MOD of AKR1C3 | <0.017 | 4 | 3 | 2 | 2 | 9 |
0.017-0.021 | 5 | 5 | 4 | 2 | 1 | |
>0.021 | 1 | 2 | 4 | 6 | 0 | |
Serum PSA | <40 ng/ml | 3 | 5 | 6 | 4 | 10 |
>40 ng/ml | 7 | 5 | 4 | 6 | 0 | |